The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
Shuichi Mitsunaga
No relevant relationships to disclose
Masafumi Ikeda
No relevant relationships to disclose
Hideki Ueno
No relevant relationships to disclose
Kohei Nakachi
No relevant relationships to disclose
Chigusa Morizane
No relevant relationships to disclose
Shunsuke Kondo
No relevant relationships to disclose
Satoshi Shimizu
No relevant relationships to disclose
Yasushi Kojima
No relevant relationships to disclose
Takuya Suzuki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Takuji Okusaka
Honoraria - Eisai